Litcius/Paper detail

USP7-Based Deubiquitinase-Targeting Chimeras Stabilize AMPK

Jing Liu, Xiaoping Hu, Kaixiu Luo, Yan Xiong, Li Chen, Zhen Wang, Hiroyuki Inuzuka, C. D. Qian, Xufen Yu, Ling Xie, Adil Muneer, Dingpeng Zhang, João A. Paulo, Xian Chen, Jian Jin, Wenyi Wei

2024Journal of the American Chemical Society29 citationsDOIOpen Access PDF

Abstract

Deubiquitinase-targeting chimeras (DUBTACs) have been recently developed to stabilize proteins of interest, which is in contrast to targeted protein degradation (TPD) approaches that degrade disease-causing proteins. However, to date, only the OTUB1 deubiquitinase has been utilized to develop DUBTACs via an OTUB1 covalent ligand, which could unexpectedly compromise the endogenous function of OTUB1 owing to its covalent nature. Here, we show for the first time that deubiquitinase USP7 can be harnessed for DUBTAC development. Based on a noncovalent ligand of USP7, we developed USP7-based DUBTACs that stabilized the ΔF508-CFTR mutant protein as effectively as the previously reported OTUB1-based DUBTAC. Importantly, using two different noncovalent ligands of USP7, we developed the first AMPK DUBTACs that appear to selectively stabilize different isoforms of AMPKβ, leading to elevated AMPK signaling. Overall, these results highlight that, in addition to OTUB1, USP7 can be leveraged to develop DUBTACs, thus significantly expanding the limited toolbox for targeted protein stabilization and the development of novel AMPK DUBTACs as potential therapeutics.

Topics & Concepts

Deubiquitinating enzymeChemistryAMPKConjugateCell biologyLigand (biochemistry)Gene isoformBiochemistryReceptorEnzymeProtein kinase AGeneUbiquitinBiologyMathematicsMathematical analysisUbiquitin and proteasome pathwaysProtein Degradation and InhibitorsAutophagy in Disease and Therapy